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1. Hepatitis C therapy
Cure of hepatitis C has come true!
Clinical care for patients with hepatitis C (HCV) has advanced remarkably during the last two 
decades, as a result of better understanding of the pathophysiology of the disease, and because of 
developments in diagnostic procedures and improvements in therapy and prevention. With the 
introduction of genotype 1 effective directly acting antiviral agents (DAAs) in 2011, the manage‐
ment of HCV infection started to change. By 2013, second-generation pangenotypic DAAs became 
available, and the biggest problem was solved: interferon (IFN) became no longer necessary.
Unlike IFN regimens, which rely on upregulating the patients’ own immune system, these 
DAAs block different stages of viral replication. There are four major groups of DAAs namely: 
NS5B nucleotide inhibitors, NS5B nonnucleoside inhibitors, NS5A replication complex inhibi‐
tors, and NS3/4A protease inhibitors [1]. Specific treatment regimens vary, depending on fac‐
tors such as HCV genotype, and may include multiple drugs [2]. Multiple regimens have been 
approved and several new regimens with high potencies, less resistance, and better safety pro‐
file are in the process of approval. Prof. Kamal elegantly describes them in detail in Chapter 2.
Sustained virological response (SVR) rates achieved in phase III clinical trials generally 
exceeded 90% (although real-world rates may be lower) along with reduction in treatment 
duration to 12 weeks or less and with fewer adverse events. An SVR is generally associated 
with normalization of liver enzymes and amelioration or disappearance of liver necroinflam‐
mation and fibrosis in noncirrhotic patients [3]. The use of DAAs in patients with cirrhosis, 
as discussed in Chapter 4, has also shown excellent results with good safety profile. SVR also 
improves HCV-induced portal hypertension [4]. DAAs have also begun to change the land‐
scape of management of the HCV transplant candidate on the waiting list. Prof. Al-Hamoudi 
provides an update on this in Chapter 5. Even patients with HCV infection and advanced 
kidney disease now have alternative treatment options.
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Thus, the era of HCV eradication and cure has begun. And in 2017, hepatologists can treat all 
patients irrespective of fibrosis score—but the job is not over yet. Real-world experience has 
revealed several challenges and unmet needs!
1.1. Challenges:
(a) Limited or absent access to therapy in the majority of infected patients
Unfortunately, the very high cost of the new DAA drugs is creating a barrier for introduc‐
tion of treatment in most limited resource settings and may prove an obstacle on the path 
for elimination of HCV infection worldwide. Of course, successful treatment should prevent 
many late HCV complications, but even if treatment actually proves cost saving in the long 
run, it is too expensive and infeasible to treat all patients immediately [5].
Hence hepatitis C treatment prioritization, as the European Association for the Study of the 
Liver states, is necessary when resources are limited [6]. However, new data suggest that this 
approach may be suboptimal, if not carefully executed. Treatment prioritization is complex 
and may not be fair. Treating first those with the most need makes sense. But, those who need 
it most may also be those who benefit the least because of issues as extensive liver damage, 
comorbid illness, older age, or have already developed hepatocellular carcinoma? Targeting 
populations with high HCV prevalence like drug users, prisoners, and migrants also makes 
sense since they are most likely to spread infection to others. But, those most likely to transmit 
to others often have low disease stage. Besides they are most likely to abrogate the personal 
benefits of treatment by being reinfected. Treating those who have the most symptoms also 
makes sense, but unfortunately symptoms do not always improve with cure. And there is 
another major issue: who should decide whom to prioritize? [7]. Health care providers often 
impose socioeconomic and racial biases when prioritizing treatments [8]. Moreover, health 
care providers prefer not to be the barrier between patients and life‐saving therapies.
While not all patients require immediate treatment, an ideal strategy should treat patients before 
they progress toward end-stage liver disease when even highly effective treatments can confer 
only marginal benefit. In response, many countries have instituted coverage policies that autho‐
rize treatment only for the advanced patients, putting off therapy for less severely ill patients [5].
Aggressive action is warranted to see progress toward HCV elimination. Only if we use effica-
cious therapy in a significant proportion of patients will we significantly decrease the burden of 
the disease. So efforts should be made to make DAAs cost effective in all clinical scenarios 
and accessible to all patients. In places like Egypt and India, generic versions of the DAAs 
sofosbuvir and daclatasvir are being mass produced for <1% of the current US retail price and 
are available for a higher proportion of patients.
Another solution to reduce treatment cost is by shortening the duration of treatment without 
affecting efficacy. A study in China demonstrated 100% SVR with triple DAAs for only 3 weeks 
if the patient without cirrhosis achieved ultra-rapid virological response (HCV-RNA < 500 IU 
48 hours after starting treatment) [9]. By shortening the duration of therapy from the currently 
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 recommended 12 to 3 weeks, the cost of therapy could be markedly reduced as well as the rate 
of adverse events. Large clinical trials should further study the application of this response‐
guided treatment approach in patients with different ethnic backgrounds and with different 
genotypes.
(b) Emergence of drug resistance and DAA failure
Despite improved SVR rates with DAA-based combination regimens, treatment fails to erad‐
icate HCV infection in 5–15%, dependening on the treatment regimen and treated popula‐
tion. Treatment failure is generally associated with the selection of HCV resistant-associated 
substitution (RAS) (or resistant-associated variant (RAV)), that is, viral molecular substitu‐
tions or variants that have reduced susceptibility to the DAA(s) administered. NS5A inhib‐
itors have a low barrier to resistance, and the variants they select confer cross‐resistance 
across all members of the drug class. Thus, NS5A resistance currently appears as the prin‐
cipal challenge of IFN-free, DAA-based therapy and they tend to persist for several years 
after treatment failure. In contrast, RASs selected by NS3/4A protease inhibitors persist for 
a much shorter time and are progressively replaced by wild‐type virus within a few months 
posttherapy. Additionally, RASs selected by the NS5B polymerase inhibitor sofosbuvir have 
poor viral fitness; thus, they rarely emerge in the presence of the drug and tend to rapidly 
disappear if selected [10]. The utility of HCV resistance testing, i.e., the determination of the 
sequence of the DAA target region prior to retreatment in patients who failed on any of the 
DAA-containing regimens is unknown. Chapter 6 summarizes the retreatment in case of 
drug failures.
(c) HCV eradication and the risk of hepatocellular carcinoma (HCC): issues with direct 
acting antiviral (DAA) therapy?
Several recent publications raise concerns about unexpected high rate of HCC recurrence 
after undergoing direct‐acting antiviral therapy. Reig et al. showed early tumor “recurrence” 
in patients with HCV-related hepatocellular carcinoma (HCC) [11]. Conti et al. showed that 
in patients with HCV-related cirrhosis, DAA-induced resolution of HCV infection does not 
reduce recurrence of HCC, and patients previously treated for HCC have still a high risk of 
tumor recurrence, in the short term [12]. Kozbial et al. showed an unexpected high “occur‐
rence” in patients with advanced liver diseases after SVR [13].
In contrast, Cheung et al. found that DAA therapy in patients with decompensated cirrhosis led 
to sustained improvement in liver function, with no evidence of increase in HCC development 
in Chinese patients [14]. Also, the French ANRS study analyzed more than 6000 DAA-treated 
patients who underwent curative therapies for HCC and they found no increased risk of HCC [15].
Altogether these studies convey a strong message that great attention is needed to address 
the issue of HCC recurrence/occurrence. There is an urgent need for large prospective stud‐
ies evaluating the impact of DAA therapy on the risk of HCC in patients with HCV-related 
cirrhosis. For the time being, the risk of HCC development justifies HCC screening after viral 
clearance in patients with HCV‐related cirrhosis.
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(d) There is no vaccine yet. Is a prophylactic vaccine still necessary?
Obviously, therapy is not enough to surmount the burden of HCV. Is it technically possible 
to have vaccine? If HCV vaccines are available in the future, then vaccination program in 
high‐risk populations would probably have a great impact on preventing and eradicating 
HCV infection. An experimental protective vaccine, as shown in Chapter 14, demonstrated 
promise in preliminary human safety trials, and a phase II clinical trial is under way to further 
determine the efficacy of the vaccine.
1.2. Future perspectives:
Therefore, although the DAAs have opened up new horizons for HCV cure, challenges per‐
sist in the real-world setting. It is becoming clear that developing therapeutic strategies with 
different modes of action would be necessary to address the various limitations of current 
DAAs. Third generation pangenotypic antivirals are currently in final phases of development: 
voxilaprevir [16], glecaprevir [17] (both NS3/NS4 protease inhibitors) and pibrentasvir (NS5A 
inhibitor) [17]. Antivirals with alternate mechanism of action, such as by restricting viral entry 
or cell-to-cell spread could help expand the scope of antiviral strategies for the management 
of hepatitis C. Chapters 14 and 15 describe some of the new paradigms in antiviral strategies 
to preclude HCV entry, such as through monoclonal antibodies and small molecules.
With these strategies, it is foreseeable, in a not too distant future, that they will help provide 
a better management of hepatitis C.
2. Hepatitis B therapy
An overview of the six currently approved treatments is presented in Chapter 7. The advent 
of anti‐HBV treatment drugs has made significant progress in improving the health and life 
expectancy of patients with HBV.
But there is no cure for Hepatitis B till now!
Chronic hepatitis B remains a difficult to treat disease because at this time no treatment pro‐
vides both an optimal virological and immunological control. There is a high rate of relapse 
following any antiviral therapy. In addition, there are no approved therapy stopping rules, 
especially in HBeAg negative patients treated with nucleoside and nucleotide analogs. An 
early stopping rule using the combination of serum HBsAg and HBV DNA was proposed and 
is discussed in Chapter 9.
While there have been significant advances in the management of hepatitis B with available 
nucleos(t)ide analogues, there remains much work to be done to prevent HCC. Viral suppres‐
sion alone has proven not effective for the absolute prevention of HCC.
Additionally, the required long-term therapy imposes not only financial burden but also may 
put patients at risk for potential drug resistance and unknown toxicity. Therefore, more effec‐
tive treatment regimens aiming for HBV cure are urgently needed. New investigational thera‐
pies are in the pipeline as discussed in Chapter 17. With multiple new therapies in the pipeline, 
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the future of treating hepatitis B is an exciting one, and there is hope that it will become a 
disease of the past but this will not be too soon! The new therapy will not be available soon.
Another challenge is a demand for screening pregnant females and newborns for HBV. 
Pregnancy screening for HBV is very defective in most countries; it is not practiced except 
on individual basis. Chapter 10 reviews current management strategies for hepatitis B in the 
pregnancy and the postpartum.
Conclusion
So, in conclusion, the highly effective and well-tolerated direct-acting antiviral drugs (DAAs) 
for the treatment of the hepatitis C virus have revolutionized therapy for HCV. Several novel 
therapeutic strategies for each of HBV and HCV are under development. But until the devel‐
oping antiviral strategies are available, there is much more that can be done.
The public health burden posed by viral hepatitis should be recognized as a priority. The 
leading professional organizations in liver disease, the American Association for the Study of 
Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and the 
Asian Pacific Association for the Study of the Liver (APASL) urge governments, health care 
organizations, and nongovernmental organizations to adopt recommendations for immuni‐
zation, screening, diagnosis and treatment and to make them available and affordable for 
public health programs [18].
Overall, the achievements and improvements in the field of HCV and HBV care predict that 
the future of HCV and HBV therapeutics is becoming brighter every day.
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